Pancreatic cancers overexpress tyrosine kinase and luteini'ng hormone-releasing hormone (LH-RH) receptor (LH-RHR)-mediated tyrosine phosphatase. LH-RHR is a 60-kDa protein. ligand showed that the LH-RH binding in 69% ofthe points was increased by EGF and 85% was decreased by RC-160 compared with controls (a ='61; both significant, P < 0.001). The specific binding was altered, increasing 50-150% after preincubation with EGF and decreasing 60-70% after RC-160. No change was seen in the binding affinity constant after pretreatment with EGF or RC-160. This shows that phosphorylation regulates binding of LB-RH and may explain the up-regulation by EGF and down-regulation by RC-160 and by LH-RH ofthe LH-RH response.Two lines of evidence suggest that the class of tyrosine phosphatases may be as important in cancer as the class of tyrosine kinases (1-3). These findings are based on the existence of a broad family of tyrosine phosphatase genes with receptor-like structures (4-8) and the demonstration that two hormone receptors stimulate tyrosine phosphatase activity (9)(10)(11)36). This has led to a rather unsuccessful attempt to implicate these genes as antioncogenes (tumor suppressor genes), or "emerogenes" (3, 12, 13). Investigators assumed that just as the expression of oncogenes in tissue heralds the development of cancer (14-17), the loss of expression of emerogenes should be associated with cancer development (12,13,18